These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32174691)

  • 1. Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL).
    Sajith M; Pawar A; Bafna V; Bartakke S; Subramanian K; Vaidya N
    Indian J Hematol Blood Transfus; 2020 Jan; 36(1):51-58. PubMed ID: 32174691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
    Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
    J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
    Chen AR; Wang YM; Lin M; Kuo DJ
    Cureus; 2020 Jun; 12(6):e8674. PubMed ID: 32699674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
    Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate.
    Özdemir ZC; Bozkurt Turhan A; Düzenli Kar Y; Bör Ö
    Int J Pediatr Adolesc Med; 2016 Dec; 3(4):162-168. PubMed ID: 30805487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.
    Mandal P; Samaddar S; Chandra J; Parakh N; Goel M
    Indian J Hematol Blood Transfus; 2020 Jul; 36(3):498-504. PubMed ID: 32647424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.
    Kapoor G; Sinha R; Abedin S
    Pediatr Blood Cancer; 2012 Sep; 59(3):448-53. PubMed ID: 22271707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
    Khera S; Kapoor R; Pramanik SK
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of serum albumin level on high-dose methotrexate induced toxicities in acute lymphoblastic leukemia patients.
    Mirza MA; D Aruna ; Konatam ML
    Int J Health Sci (Qassim); 2023; 17(2):3-9. PubMed ID: 36891042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
    Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
    Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.
    Tiwari P; Thomas MK; Pathania S; Dhawan D; Gupta YK; Vishnubhatla S; Bakhshi S
    Pediatr Hematol Oncol; 2015; 32(8):576-84. PubMed ID: 26558505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using a Bedside Algorithm to Individually Dose High-dose Methotrexate for Patients at Risk for Toxicity.
    Foster JH; Bernhardt MB; Thompson PA; Smith EO; Schafer ES
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):72-76. PubMed ID: 27820134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
    Xu W; Tang Y; Song H; Shi S; Yang S
    J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
    Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
    J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of Delivering High-Dose Methotrexate in Adolescent and Adult All Patients: A Retrospective Study.
    Shenoy R; Panda G; Bonda VNA; Sengar M; Thorat J; Jain H
    Indian J Hematol Blood Transfus; 2022 Oct; 38(4):638-642. PubMed ID: 36258731
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.
    Vila R; Rubio-San-Simón A; Zubiaur P; Navares-Gómez M; Gómez-Hernández P; Arce B; Madero L
    EJHaem; 2023 Nov; 4(4):1052-1058. PubMed ID: 38024601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
    Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.